A single-arm, phase II exploratory clinical study of camrelizumab combined with chemotherapy in neoadjuvant therapy for esophageal cancer
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Camrelizumab (Primary) ; Nedaplatin (Primary) ; Paclitaxel (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Nov 2024 Results (n=32) to predict the response to neoadjuvant camrelizumab plus chemotherapy, published in the Journal of Nuclear Medicine
- 24 Oct 2023 Results (n=70; From Aug 13, 2021, to Jul 9, 2022) assessing the efficacy and safety of neoadjuvant therapy of camrelizumab, combined with chemotherapy in resectable esophageal squamous cell cancer patients, presented at the 48th European Society for Medical Oncology Congress.
- 21 Oct 2022 New trial record